Get Prepared for Your RAC-US Exam With Actual 100 Questions
Valid RAC-US Test Answers Full-length Practice Certification Exams
A few advantages of getting the RAPS RAC-US Certification:
There are many benefits of having a RAPS RAC-US Certification, by preparing with the help of the RAC-US exam dumps. Here are the advantages of RAPS RAC-US Certification:
Recognition: The RAC program provides recognition to the individuals who have achieved the certification. The RAC-US Certification also provides job opportunities and recognition to the candidates. The rate of employer sponsorship for this certification is very high. Hence, it is beneficial for all aspiring professionals and candidates.
Career growth: The RAC certification helps you to build a successful career by making you eligible to apply for high-profile positions in the pharmaceutical industry, government agencies, and non-profit organizations.
Skill & knowledge: You will be trained to handle complex regulatory affairs. Moreover, you will gain experience and expertise to get better opportunities in the regulatory affairs profession. Client expense is also saved due to the reduced turnaround time.
Increased salary: A RAC-US certified professional has an increased chance to get higher pay in their career. Companies that are looking to hire a regulatory affairs professional can consider hiring a RAC-US certified professional. You will be able to get a great advantage when you apply for the job because you have the RAC-US Certification.
Get to know about the main objectives of the RAPS RAC-US Certification Exam:
The main objective of the RAPS RAC-US Certification exam is to test your knowledge in the area of pharmaceutical and medical devices regulations and compliance. Candidates should be familiar with the current regulatory environment, as well as the latest developments in the regulatory landscape. Additionally, candidates should understand how a given company's products and services are regulated, and how those regulations affect the company. Gatherings of the knowledge of the topics covered in the exams can be found in the RAC-US exam dumps. Candidates should also have the ability to apply this knowledge to analyze and interpret the data found in various reports or articles and come up with a solution on how to regulate a company's products and services. Installed knowledge in each of these areas is essential to pass the RAC-US Certification exam.
NEW QUESTION 31
A manufacturer is involved in a recall event process for a plasma-derived product. From which stage should the manufacturer be able to trace back the product?
- A. Plasma pooling
- B. Plasma fractionation
- C. Product distribution
- D. Individual plasma donation
Answer: C
NEW QUESTION 32
A clinical study of a drug is completed to support a marketing approval application.
According to ICH, how long should a sponsor retain the clinical study essential documents?
- A. Three years after the last clinical study site was supplied with investigational drugs
- B. Until the product has been discontinued from marketing in all ICH regions
- C. For a minimum of 10 years after completion of the clinical study
- D. For at least two years after the last approval of an application in an ICH region
Answer: D
NEW QUESTION 33
Which of the following double-blind clinical trial designs would be MOST appropriate for a
Phase III study with a new product intended to treat an acute life-threatening disease with less than optimal available therapy?
- A. Active-controlled
- B. Placebo-controlled
- C. Dose-ranging
- D. Cross-over
Answer: D
NEW QUESTION 34
The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Analyze the impact of the international monograph change on the local pharmacopeia.
- B. Prepare the international monograph change submission first and then prepare the local change when required.
- C. Transfer the notice of the upcoming international monograph change to QA for further processing.
- D. Confirm that the international monograph change is not related to local pharmacopeia.
Answer: C
NEW QUESTION 35
Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?
- A. Utilize the STED template to complete global requirements.
- B. Plan regulatory approval update meetings with senior management and stakeholders.
- C. Identify countries where special requirements exist during the product development phase.
- D. Initiate a global submission process after all submission data are finalized.
Answer: C
NEW QUESTION 36
In the process of obtaining a product approval, a regulatory affairs professional discovers that the product does not meet one of the specific technical requirements of the regulation.
However, competitors with substantially similar products have claimed compliance with the requirement and received approval. Which action should the regulatory affairs professional take FIRST?
- A. Inform the regulatory authority that such a requirement is not applicable to the product.
- B. Inform the internal departments to redesign the product to comply with this requirement.
- C. Notify senior management that the product cannot be registered.
- D. Discuss with the regulatory apriority and attempt to reach an acceptable solution.
Answer: D
NEW QUESTION 37
During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.
What should be done in response to identifying the impurity?
- A. Perform an identification study, wait until the result is available, and then consider performing a non-clinical qualification study.
- B. Perform a non-clinical qualification study, wait until the result is available, and then consider performing an identification study.
- C. Perform both identification and non-clinical qualification studies concurrently.
- D. Perform either an identification study or a non-clinical qualification study.
Answer: A
NEW QUESTION 38
Company X and Company Y both have products for the treatment of rare genetic diseases.
Company X would like to acquire Company Y but does not know enough about Company Y to make an offer.
What is the MOST appropriate approach that Company X should take to acquire more information about Company Y?
- A. Request the needed information from the Board of Directors of Company Y.
- B. Enter into an agreement with Company Y to perform due diligence.
- C. Perform a thorough library search to gather detailed information on Company Y.
- D. Recruit a professional to gather confidential intelligence on Company Y.
Answer: B
NEW QUESTION 39
After submission to the regulatory authority, a substantial error was found in the application. In order to resolve this issue, what should be done FIRST?
- A. Inform upper management immediately.
- B. Verify the procedure in the regulation for the corrections.
- C. Resubmit the entire package.
- D. Contact the legal department and ask them how to proceed.
Answer: B
NEW QUESTION 40
A company receives multiple complaints regarding the text included on a recently launched product's label. What action should the regulatory affairs professional take FIRST?
- A. Inform the production team.
- B. Notify the regulatory authority.
- C. Compare the approved text with the product label
- D. Recommend an immediate product recall.
Answer: C
NEW QUESTION 41
An inspection of a manufacturing site determines that a number of manufacturing changes have been implemented without obtaining the necessary regulatory clearance. Which of the following actions should the regulatory affairs professional complete FIRST?
- A. Assess the impact of the changes.
- B. Stop product manufacturing.
- C. Establish validation procedures.
- D. Review the stability data for the changes.
Answer: B
NEW QUESTION 42
A company establishes a new medical device indication for its consumer disposable products. The regulatory affairs professional is asked to give a 30-minute training session on these products to sales representatives. Which of the following subjects is the MOST important to discuss?
- A. Risk management process
- B. Safety-related reporting
- C. Labeling
- D. Regulatory application summary
Answer: C
NEW QUESTION 43
In preparation for the development of a new line of products, a regulatory affairs professional is asked to prepare a short presentation for senior management. Which of the following topics is MOST important to cover?
- A. Previous actions taken by regulatory authorities on similar products
- B. Potential clinical sites for the Phase III clinical trial
- C. Regulatory requirements for labeling and packaging
- D. Capacity of the manufacturing facilities to fully produce the new product
Answer: A
NEW QUESTION 44
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?
- A. Class D
- B. Class A
- C. Class B
- D. Class C
Answer: D
NEW QUESTION 45
Which of the following statements regarding export regulations for an approved product is CORRECT?
- A. The product must not be sold or offered for sale in domestic commerce.
- B. The product must not be in conflict with the laws of the country to which it is intended for export.
- C. The product must not be in accord with the specifications of the foreign purchaser.
- D. The product must not be labeled on the outside of the shipping package that it is intended for export.
Answer: B
NEW QUESTION 46
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. List of lECs or lRBs
- B. Randomization scheme and codes
- C. Detailed CV of all investigators
- D. Protocol and protocol amendments
Answer: C
NEW QUESTION 47
A company is developing a novel drug to combat AIDS. The preliminary results are very promising and include instances of complete remission. The company has been granted patents in multiple countries for the drug. The regulatory affairs professional is asked to prepare a brief report concerning potential problems for marketing of the product worldwide. Which of the following is the MOST important consideration to discuss?
- A. The stability of the drug in all zone conditions
- B. International import and export regulations
- C. The time frame in which the patent will expire
- D. Doha Declaration in the TRIPS Agreement
Answer: A
NEW QUESTION 48
A materials supplier informs a company that it intends to stop supplying a material critical to the manufacture of the company's products. What action should the company take FIRST?
- A. Review the company's existing Quality Management System
- B. Qualify another supplier and execute a supplier agreement.
- C. Complete a gap analysis to identify options.
- D. Reformulate the products with a replacement material.
Answer: B
NEW QUESTION 49
At a recent scientific meeting, Company Y had two booths:
* At one booth, Company Y provided brochures on a completed Phase II study.
* In an adjacent booth, Company Y's sales professionals were promoting one of Company
Y's marketed products.
A regulatory affairs-professional at Company X sends a letter to a counterpart at Company
Y requesting that Company Y stop this practice in the future and demanding a formal response to the letter. How should the regulatory affairs professional at Company Y BEST respond?
- A. Acknowledge receipt of the letter in a written response but do nothing further.
- B. Inform the local regulatory authority of the letter and discuss how to respond.
- C. Inform the legal department of the letter and discuss how to respond.
- D. Inform Company X that it has no right to send such a letter and do nothing further.
Answer: C
NEW QUESTION 50
A company's product was approved by a regulatory authority with the condition that further studies must be completed prior to full approval of the product.
To minimize product-associated risk to patients during the period of conditional approval, what is the LEAST effective way to achieve this goal?
- A. Promote off-label use to a carefully selected patient population.
- B. Educate patients and healthcare providers on how to use the product
- C. Delay product launch until required studies are completed.
- D. Label the product for use in appropriate populations.
Answer: A
NEW QUESTION 51
Which of the following criteria is MOST appropriate to define the animal species needed for the pre-clinical toxicity testing of a biotechnology product?
- A. Proposed dose and volume of administration
- B. Immunochemical and functional tests
- C. Proposed product route and frequency of administration
- D. Biological activity with species and/or tissue specificity
Answer: D
NEW QUESTION 52
When applying for marketing approval of a drug for a rare disease, which requirement can be waived?
- A. Phase I clinical trials
- B. Phase III clinical trials
- C. Phase I and II clinical trials
- D. Pre-clinical studies
Answer: B
NEW QUESTION 53
According to ICH, how many stability time points are normally required to establish a two- year shelf life for a product?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: D
NEW QUESTION 54
A company is developing a line of products for which no ISO standard of performance is available. As a result, the company wishes to propose developing such a standard. Whom should the company contact in order to start the development of the new standard?
- A. The country's regulatory authority
- B. The ISO Secretariat
- C. The ISO national member body
- D. The ISO technical committee in charge of the area
Answer: C
NEW QUESTION 55
......
Accurate & Verified 2022 New RAC-US Answers As Experienced in the Actual Test!: https://www.ipassleader.com/RAPS/RAC-US-practice-exam-dumps.html
RAC-US Certification Sample Questions certification Exam: https://drive.google.com/open?id=13GBNXcnJPKXn7nH8tCdN7-HWvW1n49OA